REG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Signing of Strategic Platform License

MaxCyteAnnouncement

16/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240916:nRSP2334Ea&default-theme=true

RNS Number : 2334E  MaxCyte, Inc.  16 September 2024

 

MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate
the Development of Cell Therapies for Genetic Diseases

 

Kamau to use MaxCyte's Flow Electroporation® technology and ExPERT™
platform to support its homology-directed repair (HDR) novel gene correction
technology

 

Rockville, MD, and South San Francisco, CA, Sept. 16, 2024 - MaxCyte, Inc.
(https://protect.checkpoint.com/v2/___https:/maxcyte.com/___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzo5NGRhMmRhOGUwZjZhMzIxM2QzMTEzMDQ2YjA0ZjQzYjo2Ojk2MGQ6M2Q0Y2M0Y2IyMzI3OGExYjcwZmZiN2YxMzNhMDYzYmY2YzNiMDBiMzZlMDQwNGVmM2JmOTc2M2U1NDMxYTc2YzpwOkY6Rg)
, (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company
providing enabling platform technologies to advance the discovery, development
and commercialization of next-generation cell-based therapeutics and
innovative bioprocessing applications, and Kamau Therapeutics
(https://protect.checkpoint.com/v2/___https:/kamautx.com/___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzo5NGRhMmRhOGUwZjZhMzIxM2QzMTEzMDQ2YjA0ZjQzYjo2OmViNzg6MzBkMjZkNjFmZjA0NWI0OTQ2ZmEzODFkZjI3YmQ0ZmVkY2Q2NjAyNDRmNjlhMTU5MWEyYTI2Yjg1M2UwZWQ3OTpwOkY6Rg)
, a clinical-stage stem cell therapy gene correction company, today announced
they are entering into a strategic platform license (SPL) agreement.

 

Under the terms of the agreement, Kamau obtains non-exclusive research,
clinical and commercial rights to use MaxCyte's Flow Electroporation®
technology and ExPERT™ platform. In return, MaxCyte is entitled to receive
annual licensing fees and program-related revenue.

 

Kamau is a clinical-stage, next-generation gene correction company harnessing
high efficiency targeted gene integration to develop a new class of therapies
with the aim to cure a wide range of serious and life-threatening diseases,
such as sickle cell disease (SCD). The company's platform, which is founded on
homology-directed repair (HDR) editing, builds on first generation CRISPR-Cas9
technology by not only cutting DNA but providing a template to repair DNA. HDR
now forms the basis for Kamau's lead investigational program, nula-cel, which
is in clinical development for SCD.

 

"Bringing this groundbreaking gene therapy research into the clinic requires a
robust manufacturing process and the ability to scale," said Maher Masoud,
President and CEO of MaxCyte. "By partnering with us, Kamau gains access
to our commercially validated Flow Electroporation technology as well as
technical, regulatory and scientific support. This enables them to optimize
their clinical manufacturing process, mitigate risks and expedite the
progression of their lead product candidate through clinical phases to deliver
this potential cure to patients living with SCD."

 

"HDR overcomes prior limitations in specificity, efficiency and durability of
gene editing to offer broad potential for transforming human health outcomes
through the delivery of one-time curative cell therapies," said Matthew
Porteus, MD, PhD, Co-Founder of Kamau. "Through our collaboration with MaxCyte
and the use of their proven non-viral platform, our goal is to treat or cure a
range of serious genetic diseases with unmet medical needs using
homology-directed repair."

 

MaxCyte's ExPERT™ instrument portfolio is the next generation of leading,
clinically and commercially validated electroporation technology for complex
and scalable cell engineering. By delivering high transfection efficiency,
seamless scalability and enhanced functionality, the ExPERT™ platform
delivers the high-end performance essential to enabling the next wave of
biological and cellular therapeutics. Kamau Therapeutics is MaxCyte's 29th
clinical/commercial partnership overall; each partnership generates
pre-commercial milestone revenue, the vast majority of which includes
program-related revenue.

 

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of
cells to improve patients' lives. We have spent more than 20 years honing our
expertise by building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond today's processes to innovate
tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow
Electroporation® technology, has been designed to support the rapidly
expanding cell therapy market and can be utilized across the continuum of the
high-growth cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The ExPERT family
of products includes: four instruments, the ATx™, STx™, GTx™ and VLx
™; a portfolio of proprietary related processing assemblies or disposables;
and software protocols, all supported by a robust worldwide intellectual
property portfolio. By providing our partners with the right technology
platform, as well as technical and regulatory support, we aim to guide them on
their journey to transform human health. Learn more at maxcyte.com
(https://protect.checkpoint.com/v2/___https:/maxcyte.com/___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzo5NGRhMmRhOGUwZjZhMzIxM2QzMTEzMDQ2YjA0ZjQzYjo2Ojk2MGQ6M2Q0Y2M0Y2IyMzI3OGExYjcwZmZiN2YxMzNhMDYzYmY2YzNiMDBiMzZlMDQwNGVmM2JmOTc2M2U1NDMxYTc2YzpwOkY6Rg)
and follow us on X
(https://protect.checkpoint.com/v2/___https:/twitter.com/MaxCyte_info___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzo5NGRhMmRhOGUwZjZhMzIxM2QzMTEzMDQ2YjA0ZjQzYjo2OjkwYTY6MjIxN2VkNGQ0ODFkOTUxMjU1NTEzZGFjNzY3MzBhOGI4NjQwM2Y0N2UzODQ4ZDVmZmZiY2RjZGI0YTMyMjI5YTpwOkY6Rg)
and LinkedIn
(https://protect.checkpoint.com/v2/___https:/www.linkedin.com/company/maxcyte-inc-/___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzo5NGRhMmRhOGUwZjZhMzIxM2QzMTEzMDQ2YjA0ZjQzYjo2OmE3NzM6M2JiYzA2YTA5MzlkNDAxYTdlZTdlNmM3NWRmMjRjZjVhYmVlNmIzZTNlM2VkYjI0YTlkOWM3ZjBlNjdmY2U3NTpwOkY6Rg)
.

 

About Kamau Therapeutics

Kamau Therapeutics is a clinical-stage, gene correction company dedicated to
transforming the lives of patients with devastating genetic diseases through
best-in-class, curative stem-cell therapies. Kamau stands apart through the
unique capabilities of its next-generation gene correction platform that
directly corrects genetic mutations with unprecedented precision: removing the
pathologic mutation and replacing it with the healthy version. The company's
platform technology is based on the pioneering research of company co-founder
Matthew Porteus, MD, PhD, and offers broad potential for transforming human
health. Kamau's lead clinical program, nulabeglogene autogedtemcel (nula-cel),
previously developed by Graphite Bio, is the only hematopoietic stem-cell
based therapy in clinical development for sickle cell disease (SCD) that
precisely corrects the mutation in the beta-globin gene found in the sickled
hemoglobin (HgbS) of SCD patients, restoring patient's stem cells to normal
adult hemoglobin (HgbA). Kamau plans to enroll additional patients with SCD in
the Phase 1/2 clinical trial of nula-cel, for which it has received both fast
track and orphan drug designations from the U.S. Food and Drug Administration
(FDA). For more information, please visit kamautx.com
(https://protect.checkpoint.com/v2/___https:/kamautx.com/___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzo5NGRhMmRhOGUwZjZhMzIxM2QzMTEzMDQ2YjA0ZjQzYjo2OmViNzg6MzBkMjZkNjFmZjA0NWI0OTQ2ZmEzODFkZjI3YmQ0ZmVkY2Q2NjAyNDRmNjlhMTU5MWEyYTI2Yjg1M2UwZWQ3OTpwOkY6Rg)
and follow the company's progress on its LinkedIn
(https://protect.checkpoint.com/v2/___https:/www.linkedin.com/company/kamau-therapeutics/___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzo5NGRhMmRhOGUwZjZhMzIxM2QzMTEzMDQ2YjA0ZjQzYjo2OmE1NWQ6OGM0YWJjZWNjN2E2NWRjYzdiOTYyOTU4NmRlZThjYmZiMzQ5ZGJmZjVhNWU0NzVjZTM3NDUwMjlhNDI4NGExYjpwOkY6Rg)
 page.

 

MaxCyte Contacts:

 

US IR Adviser

Gilmartin Group

David Deuchler, CFA

+1 415-937-5400

ir@maxcyte.com (mailto:ir@maxcyte.com)

 

US Media Relations

Spectrum Science

Jordan Vines

jvines@spectrumscience.com (mailto:jvines@spectrumscience.com)

+1 540-629-3137

 

Nominated Adviser and Joint Corporate Broker

Panmure Liberum

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

+44 (0)20 7886 2500

 

UK IR Adviser

ICR Consilium

Mary-Jane Elliott

Chris Welsh

+44 (0)203 709 5700

maxcyte@consilium-comms.com (mailto:maxcyte@consilium-comms.com)

 

Kamau Contacts:

Kamau Therapeutics
Laura Henry

+1-415-980-0256

E: lhenry@kamautx.com (mailto:lhenry@kamautx.com)

 

Forward-Looking Statements

 

This press release contains "forward-looking statements" within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995.  All statements other than statements of historical facts contained
in this this press release, including statements regarding our future results
of operations or financial condition, business strategy and plans and
objectives of management for future operations, are forward-looking
statements. These statements are inherently uncertain, and investors are
cautioned not to unduly rely on these statements.

 

Risks and uncertainties related to our business are described in greater
detail in Item 1A  of our Annual Report on Form 10-K for the year ended
December 31, 2023, filed with the Securities and Exchange Commission ("SEC")
on March 12, 2024, as well as in discussions of potential risks,
uncertainties, and other important factors in the other filings that we make
with the Securities and Exchange Commission from time to time, including in
our Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on
August 6, 2024. These documents are available through the Investor Menu,
Financials section, under "SEC Filings" on the Investors page of our website
at http://investors.maxcyte.com
(https://protect.checkpoint.com/v2/___http:/investors.maxcyte.com/___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzo5NGRhMmRhOGUwZjZhMzIxM2QzMTEzMDQ2YjA0ZjQzYjo2Ojc2YjE6MTU1NzE1M2U0MjVhMzg4OWYzMTkwZjA3Y2NmYWFiYjBjNGVkZTNkZjZmYTMyYWY3MTVmZjRkZmYyNGYxZTIxODpwOkY6Rg)
. Any forward-looking statements in this press release are based on our
current beliefs and opinions on the relevant subject based on information
available to us as of the date of such press release, and you should not rely
on forward-looking statements as predictions of future events. We undertake no
obligation to update any forward-looking statements made in this press release
to reflect events or circumstances after the date of this press release or to
reflect new information or the occurrence of unanticipated events, except as
required by law.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRUVURRSSUKAUR